nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—UGT1A9—Mycophenolic acid—systemic scleroderma	0.229	0.338	CbGbCtD
Haloperidol—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.128	0.189	CbGbCtD
Haloperidol—CYP1A2—Pentoxifylline—systemic scleroderma	0.0402	0.0595	CbGbCtD
Haloperidol—CYP1A2—Leflunomide—systemic scleroderma	0.0384	0.0567	CbGbCtD
Haloperidol—ABCB1—Lisinopril—systemic scleroderma	0.0352	0.052	CbGbCtD
Haloperidol—CYP2C9—Leflunomide—systemic scleroderma	0.0346	0.0511	CbGbCtD
Haloperidol—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0319	0.0471	CbGbCtD
Haloperidol—ABCB1—Captopril—systemic scleroderma	0.0263	0.0389	CbGbCtD
Haloperidol—CYP2D6—Captopril—systemic scleroderma	0.0248	0.0367	CbGbCtD
Haloperidol—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0207	0.0306	CbGbCtD
Haloperidol—CYP2C19—Prednisone—systemic scleroderma	0.0205	0.0304	CbGbCtD
Haloperidol—HTR2B—cardial valve—systemic scleroderma	0.0183	0.206	CbGeAlD
Haloperidol—ABCB1—Prednisone—systemic scleroderma	0.0166	0.0245	CbGbCtD
Haloperidol—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0124	0.0184	CbGbCtD
Haloperidol—CYP2C9—cardial valve—systemic scleroderma	0.0118	0.133	CbGeAlD
Haloperidol—CYP3A4—Prednisone—systemic scleroderma	0.00993	0.0147	CbGbCtD
Haloperidol—ABCB1—Methotrexate—systemic scleroderma	0.00831	0.0123	CbGbCtD
Haloperidol—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00558	0.0628	CbGeAlD
Haloperidol—HTR2A—pulmonary artery—systemic scleroderma	0.00395	0.0445	CbGeAlD
Haloperidol—HTR1B—artery—systemic scleroderma	0.00304	0.0343	CbGeAlD
Haloperidol—HTR1D—artery—systemic scleroderma	0.00295	0.0332	CbGeAlD
Haloperidol—HTR1B—blood vessel—systemic scleroderma	0.00237	0.0267	CbGeAlD
Haloperidol—HTR1D—blood vessel—systemic scleroderma	0.0023	0.0258	CbGeAlD
Haloperidol—UGT1A9—digestive system—systemic scleroderma	0.00178	0.02	CbGeAlD
Haloperidol—CBR1—skin of body—systemic scleroderma	0.00167	0.0189	CbGeAlD
Haloperidol—H1F0—connective tissue—systemic scleroderma	0.00152	0.0171	CbGeAlD
Haloperidol—HTR2A—artery—systemic scleroderma	0.00146	0.0165	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—systemic scleroderma	0.00139	0.0156	CbGeAlD
Haloperidol—H1F0—skin of body—systemic scleroderma	0.00137	0.0154	CbGeAlD
Haloperidol—CBR1—digestive system—systemic scleroderma	0.00134	0.0151	CbGeAlD
Haloperidol—CBR1—tendon—systemic scleroderma	0.00127	0.0144	CbGeAlD
Haloperidol—HTR2A—endothelium—systemic scleroderma	0.00124	0.0139	CbGeAlD
Haloperidol—HTR1D—connective tissue—systemic scleroderma	0.00118	0.0133	CbGeAlD
Haloperidol—HTR2A—blood vessel—systemic scleroderma	0.00114	0.0128	CbGeAlD
Haloperidol—CBR1—lung—systemic scleroderma	0.00112	0.0126	CbGeAlD
Haloperidol—H1F0—digestive system—systemic scleroderma	0.0011	0.0124	CbGeAlD
Haloperidol—H1F0—tendon—systemic scleroderma	0.00104	0.0118	CbGeAlD
Haloperidol—SIGMAR1—smooth muscle tissue—systemic scleroderma	0.001	0.0113	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—systemic scleroderma	0.001	0.0113	CbGeAlD
Haloperidol—HTR2B—skin of body—systemic scleroderma	0.000989	0.0111	CbGeAlD
Haloperidol—H1F0—lung—systemic scleroderma	0.000917	0.0103	CbGeAlD
Haloperidol—HTR2B—digestive system—systemic scleroderma	0.000791	0.0089	CbGeAlD
Haloperidol—SIGMAR1—tendon—systemic scleroderma	0.000754	0.00849	CbGeAlD
Haloperidol—HTR2B—tendon—systemic scleroderma	0.000753	0.00847	CbGeAlD
Haloperidol—ABCB1—blood vessel—systemic scleroderma	0.000747	0.00841	CbGeAlD
Haloperidol—HRH1—connective tissue—systemic scleroderma	0.0007	0.00788	CbGeAlD
Haloperidol—CYP1A1—skin of body—systemic scleroderma	0.000666	0.0075	CbGeAlD
Haloperidol—SIGMAR1—lung—systemic scleroderma	0.000662	0.00745	CbGeAlD
Haloperidol—CYP2C19—digestive system—systemic scleroderma	0.000661	0.00744	CbGeAlD
Haloperidol—HTR2B—lung—systemic scleroderma	0.000661	0.00744	CbGeAlD
Haloperidol—HRH1—smooth muscle tissue—systemic scleroderma	0.000641	0.00721	CbGeAlD
Haloperidol—HTR2A—connective tissue—systemic scleroderma	0.000585	0.00658	CbGeAlD
Haloperidol—CYP1A2—digestive system—systemic scleroderma	0.00054	0.00608	CbGeAlD
Haloperidol—HTR2A—smooth muscle tissue—systemic scleroderma	0.000535	0.00602	CbGeAlD
Haloperidol—DRD2—lung—systemic scleroderma	0.000535	0.00602	CbGeAlD
Haloperidol—CYP1A1—digestive system—systemic scleroderma	0.000533	0.006	CbGeAlD
Haloperidol—CYP3A5—digestive system—systemic scleroderma	0.000521	0.00586	CbGeAlD
Haloperidol—CYP2C9—digestive system—systemic scleroderma	0.000513	0.00577	CbGeAlD
Haloperidol—HRH1—digestive system—systemic scleroderma	0.000506	0.00569	CbGeAlD
Haloperidol—HRH1—tendon—systemic scleroderma	0.000481	0.00542	CbGeAlD
Haloperidol—CYP1A2—lung—systemic scleroderma	0.000451	0.00508	CbGeAlD
Haloperidol—CYP1A1—lung—systemic scleroderma	0.000445	0.00501	CbGeAlD
Haloperidol—CYP3A5—lung—systemic scleroderma	0.000435	0.0049	CbGeAlD
Haloperidol—HTR2A—digestive system—systemic scleroderma	0.000422	0.00475	CbGeAlD
Haloperidol—HRH1—lung—systemic scleroderma	0.000422	0.00475	CbGeAlD
Haloperidol—HTR2A—tendon—systemic scleroderma	0.000402	0.00452	CbGeAlD
Haloperidol—CYP3A4—digestive system—systemic scleroderma	0.000391	0.0044	CbGeAlD
Haloperidol—CYP2D6—digestive system—systemic scleroderma	0.000385	0.00433	CbGeAlD
Haloperidol—HTR2A—lung—systemic scleroderma	0.000353	0.00397	CbGeAlD
Haloperidol—Oedema—Mycophenolic acid—systemic scleroderma	0.00031	0.00132	CcSEcCtD
Haloperidol—Anorexia—Leflunomide—systemic scleroderma	0.00031	0.00132	CcSEcCtD
Haloperidol—Nausea—Pentoxifylline—systemic scleroderma	0.000309	0.00132	CcSEcCtD
Haloperidol—Vertigo—Lisinopril—systemic scleroderma	0.000307	0.00131	CcSEcCtD
Haloperidol—Diarrhoea—Mometasone—systemic scleroderma	0.000307	0.00131	CcSEcCtD
Haloperidol—Leukopenia—Lisinopril—systemic scleroderma	0.000306	0.0013	CcSEcCtD
Haloperidol—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000304	0.0013	CcSEcCtD
Haloperidol—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000304	0.00129	CcSEcCtD
Haloperidol—Hypotension—Leflunomide—systemic scleroderma	0.000304	0.00129	CcSEcCtD
Haloperidol—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000303	0.00129	CcSEcCtD
Haloperidol—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000302	0.00129	CcSEcCtD
Haloperidol—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000302	0.00128	CcSEcCtD
Haloperidol—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000301	0.00128	CcSEcCtD
Haloperidol—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.0003	0.00128	CcSEcCtD
Haloperidol—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.0003	0.00128	CcSEcCtD
Haloperidol—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000299	0.00127	CcSEcCtD
Haloperidol—Visual disturbance—Methotrexate—systemic scleroderma	0.000297	0.00127	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000297	0.00126	CcSEcCtD
Haloperidol—Anorexia—Mycophenolic acid—systemic scleroderma	0.000295	0.00126	CcSEcCtD
Haloperidol—Insomnia—Leflunomide—systemic scleroderma	0.000294	0.00125	CcSEcCtD
Haloperidol—Anxiety—Lisinopril—systemic scleroderma	0.00029	0.00124	CcSEcCtD
Haloperidol—Dyspnoea—Leflunomide—systemic scleroderma	0.00029	0.00123	CcSEcCtD
Haloperidol—Hypotension—Mycophenolic acid—systemic scleroderma	0.00029	0.00123	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000289	0.00123	CcSEcCtD
Haloperidol—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000288	0.00123	CcSEcCtD
Haloperidol—Lethargy—Methotrexate—systemic scleroderma	0.000288	0.00123	CcSEcCtD
Haloperidol—Dyspepsia—Leflunomide—systemic scleroderma	0.000286	0.00122	CcSEcCtD
Haloperidol—Vomiting—Mometasone—systemic scleroderma	0.000285	0.00122	CcSEcCtD
Haloperidol—Dry mouth—Lisinopril—systemic scleroderma	0.000285	0.00121	CcSEcCtD
Haloperidol—Sweating increased—Prednisone—systemic scleroderma	0.000284	0.00121	CcSEcCtD
Haloperidol—Feeling abnormal—Azathioprine—systemic scleroderma	0.000283	0.00121	CcSEcCtD
Haloperidol—Rash—Mometasone—systemic scleroderma	0.000283	0.00121	CcSEcCtD
Haloperidol—Dermatitis—Mometasone—systemic scleroderma	0.000283	0.0012	CcSEcCtD
Haloperidol—Decreased appetite—Leflunomide—systemic scleroderma	0.000282	0.0012	CcSEcCtD
Haloperidol—Confusional state—Lisinopril—systemic scleroderma	0.000281	0.0012	CcSEcCtD
Haloperidol—Headache—Mometasone—systemic scleroderma	0.000281	0.0012	CcSEcCtD
Haloperidol—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000281	0.0012	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00028	0.00119	CcSEcCtD
Haloperidol—Insomnia—Mycophenolic acid—systemic scleroderma	0.00028	0.00119	CcSEcCtD
Haloperidol—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000279	0.00119	CcSEcCtD
Haloperidol—Oedema—Lisinopril—systemic scleroderma	0.000279	0.00119	CcSEcCtD
Haloperidol—Pruritus—Captopril—systemic scleroderma	0.000279	0.00119	CcSEcCtD
Haloperidol—Constipation—Leflunomide—systemic scleroderma	0.000278	0.00118	CcSEcCtD
Haloperidol—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000277	0.00118	CcSEcCtD
Haloperidol—ABCB1—digestive system—systemic scleroderma	0.000277	0.00312	CbGeAlD
Haloperidol—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000276	0.00118	CcSEcCtD
Haloperidol—Somnolence—Mycophenolic acid—systemic scleroderma	0.000276	0.00117	CcSEcCtD
Haloperidol—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000275	0.00117	CcSEcCtD
Haloperidol—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000273	0.00116	CcSEcCtD
Haloperidol—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000273	0.00116	CcSEcCtD
Haloperidol—Neutropenia—Prednisone—systemic scleroderma	0.000273	0.00116	CcSEcCtD
Haloperidol—Tachycardia—Lisinopril—systemic scleroderma	0.000272	0.00116	CcSEcCtD
Haloperidol—Body temperature increased—Azathioprine—systemic scleroderma	0.000272	0.00116	CcSEcCtD
Haloperidol—Skin disorder—Lisinopril—systemic scleroderma	0.000271	0.00115	CcSEcCtD
Haloperidol—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00027	0.00115	CcSEcCtD
Haloperidol—Diarrhoea—Captopril—systemic scleroderma	0.00027	0.00115	CcSEcCtD
Haloperidol—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000269	0.00115	CcSEcCtD
Haloperidol—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000269	0.00115	CcSEcCtD
Haloperidol—Erectile dysfunction—Prednisone—systemic scleroderma	0.000269	0.00114	CcSEcCtD
Haloperidol—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000268	0.00114	CcSEcCtD
Haloperidol—Feeling abnormal—Leflunomide—systemic scleroderma	0.000268	0.00114	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000268	0.00114	CcSEcCtD
Haloperidol—Nausea—Mometasone—systemic scleroderma	0.000267	0.00114	CcSEcCtD
Haloperidol—Anorexia—Lisinopril—systemic scleroderma	0.000266	0.00113	CcSEcCtD
Haloperidol—Weight increased—Prednisone—systemic scleroderma	0.000265	0.00113	CcSEcCtD
Haloperidol—Constipation—Mycophenolic acid—systemic scleroderma	0.000265	0.00113	CcSEcCtD
Haloperidol—Weight decreased—Prednisone—systemic scleroderma	0.000264	0.00112	CcSEcCtD
Haloperidol—Hyperglycaemia—Prednisone—systemic scleroderma	0.000263	0.00112	CcSEcCtD
Haloperidol—Hypotension—Lisinopril—systemic scleroderma	0.000261	0.00111	CcSEcCtD
Haloperidol—Dizziness—Captopril—systemic scleroderma	0.000261	0.00111	CcSEcCtD
Haloperidol—Liver function test abnormal—Methotrexate—systemic scleroderma	0.00026	0.00111	CcSEcCtD
Haloperidol—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00026	0.00111	CcSEcCtD
Haloperidol—Depression—Prednisone—systemic scleroderma	0.000259	0.0011	CcSEcCtD
Haloperidol—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000259	0.0011	CcSEcCtD
Haloperidol—Urticaria—Leflunomide—systemic scleroderma	0.000258	0.0011	CcSEcCtD
Haloperidol—Body temperature increased—Leflunomide—systemic scleroderma	0.000257	0.00109	CcSEcCtD
Haloperidol—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000255	0.00109	CcSEcCtD
Haloperidol—Breast disorder—Methotrexate—systemic scleroderma	0.000255	0.00108	CcSEcCtD
Haloperidol—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000254	0.00108	CcSEcCtD
Haloperidol—Hypersensitivity—Azathioprine—systemic scleroderma	0.000253	0.00108	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00108	CcSEcCtD
Haloperidol—Insomnia—Lisinopril—systemic scleroderma	0.000252	0.00108	CcSEcCtD
Haloperidol—Vomiting—Captopril—systemic scleroderma	0.000251	0.00107	CcSEcCtD
Haloperidol—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00025	0.00106	CcSEcCtD
Haloperidol—Dyspnoea—Lisinopril—systemic scleroderma	0.000249	0.00106	CcSEcCtD
Haloperidol—Rash—Captopril—systemic scleroderma	0.000249	0.00106	CcSEcCtD
Haloperidol—Dermatitis—Captopril—systemic scleroderma	0.000248	0.00106	CcSEcCtD
Haloperidol—Somnolence—Lisinopril—systemic scleroderma	0.000248	0.00106	CcSEcCtD
Haloperidol—Headache—Captopril—systemic scleroderma	0.000247	0.00105	CcSEcCtD
Haloperidol—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00105	CcSEcCtD
Haloperidol—Dyspepsia—Lisinopril—systemic scleroderma	0.000246	0.00105	CcSEcCtD
Haloperidol—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000245	0.00104	CcSEcCtD
Haloperidol—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000245	0.00104	CcSEcCtD
Haloperidol—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000245	0.00104	CcSEcCtD
Haloperidol—Decreased appetite—Lisinopril—systemic scleroderma	0.000243	0.00103	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000241	0.00103	CcSEcCtD
Haloperidol—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00024	0.00102	CcSEcCtD
Haloperidol—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00102	CcSEcCtD
Haloperidol—Hypersensitivity—Leflunomide—systemic scleroderma	0.000239	0.00102	CcSEcCtD
Haloperidol—Constipation—Lisinopril—systemic scleroderma	0.000239	0.00102	CcSEcCtD
Haloperidol—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00102	CcSEcCtD
Haloperidol—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000238	0.00101	CcSEcCtD
Haloperidol—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000236	0.00101	CcSEcCtD
Haloperidol—Diarrhoea—Azathioprine—systemic scleroderma	0.000235	0.001	CcSEcCtD
Haloperidol—Nausea—Captopril—systemic scleroderma	0.000234	0.000997	CcSEcCtD
Haloperidol—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000233	0.000993	CcSEcCtD
Haloperidol—Hallucination—Prednisone—systemic scleroderma	0.000232	0.000989	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—systemic scleroderma	0.000231	0.000985	CcSEcCtD
Haloperidol—ABCB1—lung—systemic scleroderma	0.000231	0.0026	CbGeAlD
Haloperidol—Feeling abnormal—Lisinopril—systemic scleroderma	0.00023	0.00098	CcSEcCtD
Haloperidol—Pruritus—Leflunomide—systemic scleroderma	0.00023	0.000979	CcSEcCtD
Haloperidol—Connective tissue disorder—Prednisone—systemic scleroderma	0.000229	0.000977	CcSEcCtD
Haloperidol—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000229	0.000973	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—systemic scleroderma	0.000228	0.00097	CcSEcCtD
Haloperidol—Dizziness—Azathioprine—systemic scleroderma	0.000227	0.000969	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000224	0.000956	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000222	0.000947	CcSEcCtD
Haloperidol—Diarrhoea—Leflunomide—systemic scleroderma	0.000222	0.000947	CcSEcCtD
Haloperidol—Urticaria—Lisinopril—systemic scleroderma	0.000222	0.000944	CcSEcCtD
Haloperidol—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000942	CcSEcCtD
Haloperidol—Body temperature increased—Lisinopril—systemic scleroderma	0.000221	0.00094	CcSEcCtD
Haloperidol—Pruritus—Mycophenolic acid—systemic scleroderma	0.000219	0.000934	CcSEcCtD
Haloperidol—Vomiting—Azathioprine—systemic scleroderma	0.000219	0.000932	CcSEcCtD
Haloperidol—Eye disorder—Prednisone—systemic scleroderma	0.000218	0.000929	CcSEcCtD
Haloperidol—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000929	CcSEcCtD
Haloperidol—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000217	0.000926	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—systemic scleroderma	0.000217	0.000925	CcSEcCtD
Haloperidol—Rash—Azathioprine—systemic scleroderma	0.000217	0.000924	CcSEcCtD
Haloperidol—Dermatitis—Azathioprine—systemic scleroderma	0.000217	0.000923	CcSEcCtD
Haloperidol—Depression—Methotrexate—systemic scleroderma	0.000217	0.000923	CcSEcCtD
Haloperidol—Headache—Azathioprine—systemic scleroderma	0.000216	0.000918	CcSEcCtD
Haloperidol—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000917	CcSEcCtD
Haloperidol—Dizziness—Leflunomide—systemic scleroderma	0.000215	0.000915	CcSEcCtD
Haloperidol—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000906	CcSEcCtD
Haloperidol—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000212	0.000903	CcSEcCtD
Haloperidol—Angiopathy—Prednisone—systemic scleroderma	0.000212	0.000902	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000211	0.000899	CcSEcCtD
Haloperidol—Immune system disorder—Prednisone—systemic scleroderma	0.000211	0.000898	CcSEcCtD
Haloperidol—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000891	CcSEcCtD
Haloperidol—Vomiting—Leflunomide—systemic scleroderma	0.000207	0.00088	CcSEcCtD
Haloperidol—Alopecia—Prednisone—systemic scleroderma	0.000206	0.000878	CcSEcCtD
Haloperidol—Hypersensitivity—Lisinopril—systemic scleroderma	0.000206	0.000876	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000205	0.000875	CcSEcCtD
Haloperidol—Dizziness—Mycophenolic acid—systemic scleroderma	0.000205	0.000873	CcSEcCtD
Haloperidol—Rash—Leflunomide—systemic scleroderma	0.000205	0.000872	CcSEcCtD
Haloperidol—Dermatitis—Leflunomide—systemic scleroderma	0.000205	0.000872	CcSEcCtD
Haloperidol—Mental disorder—Prednisone—systemic scleroderma	0.000204	0.000871	CcSEcCtD
Haloperidol—Nausea—Azathioprine—systemic scleroderma	0.000204	0.00087	CcSEcCtD
Haloperidol—Headache—Leflunomide—systemic scleroderma	0.000204	0.000867	CcSEcCtD
Haloperidol—Malnutrition—Prednisone—systemic scleroderma	0.000203	0.000865	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—systemic scleroderma	0.000203	0.000863	CcSEcCtD
Haloperidol—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000858	CcSEcCtD
Haloperidol—Pruritus—Lisinopril—systemic scleroderma	0.000198	0.000841	CcSEcCtD
Haloperidol—Vomiting—Mycophenolic acid—systemic scleroderma	0.000197	0.000839	CcSEcCtD
Haloperidol—Rash—Mycophenolic acid—systemic scleroderma	0.000195	0.000832	CcSEcCtD
Haloperidol—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000195	0.000831	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—systemic scleroderma	0.000195	0.000831	CcSEcCtD
Haloperidol—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000828	CcSEcCtD
Haloperidol—Headache—Mycophenolic acid—systemic scleroderma	0.000194	0.000827	CcSEcCtD
Haloperidol—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000823	CcSEcCtD
Haloperidol—Nausea—Leflunomide—systemic scleroderma	0.000193	0.000822	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000193	0.00082	CcSEcCtD
Haloperidol—Vision blurred—Prednisone—systemic scleroderma	0.000191	0.000815	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—systemic scleroderma	0.000191	0.000814	CcSEcCtD
Haloperidol—Diarrhoea—Lisinopril—systemic scleroderma	0.000191	0.000813	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—systemic scleroderma	0.000188	0.0008	CcSEcCtD
Haloperidol—Anaemia—Prednisone—systemic scleroderma	0.000188	0.0008	CcSEcCtD
Haloperidol—Agitation—Prednisone—systemic scleroderma	0.000187	0.000795	CcSEcCtD
Haloperidol—Dizziness—Lisinopril—systemic scleroderma	0.000185	0.000786	CcSEcCtD
Haloperidol—Nausea—Mycophenolic acid—systemic scleroderma	0.000184	0.000784	CcSEcCtD
Haloperidol—Vertigo—Prednisone—systemic scleroderma	0.000183	0.000777	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—systemic scleroderma	0.000182	0.000776	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—systemic scleroderma	0.000181	0.000771	CcSEcCtD
Haloperidol—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000767	CcSEcCtD
Haloperidol—Vomiting—Lisinopril—systemic scleroderma	0.000177	0.000756	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—systemic scleroderma	0.000177	0.000754	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—systemic scleroderma	0.000176	0.00075	CcSEcCtD
Haloperidol—Rash—Lisinopril—systemic scleroderma	0.000176	0.00075	CcSEcCtD
Haloperidol—Convulsion—Prednisone—systemic scleroderma	0.000176	0.00075	CcSEcCtD
Haloperidol—Dermatitis—Lisinopril—systemic scleroderma	0.000176	0.000749	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000176	0.000749	CcSEcCtD
Haloperidol—Hypertension—Prednisone—systemic scleroderma	0.000175	0.000747	CcSEcCtD
Haloperidol—Headache—Lisinopril—systemic scleroderma	0.000175	0.000745	CcSEcCtD
Haloperidol—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000173	0.000737	CcSEcCtD
Haloperidol—Anxiety—Prednisone—systemic scleroderma	0.000172	0.000734	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—systemic scleroderma	0.000172	0.000734	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000172	0.000731	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—systemic scleroderma	0.000171	0.000728	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—systemic scleroderma	0.00017	0.000723	CcSEcCtD
Haloperidol—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000713	CcSEcCtD
Haloperidol—Nausea—Lisinopril—systemic scleroderma	0.000166	0.000706	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—systemic scleroderma	0.000166	0.000706	CcSEcCtD
Haloperidol—Oedema—Prednisone—systemic scleroderma	0.000166	0.000706	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—systemic scleroderma	0.000163	0.000692	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—systemic scleroderma	0.000162	0.000689	CcSEcCtD
Haloperidol—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000689	CcSEcCtD
Haloperidol—Skin disorder—Prednisone—systemic scleroderma	0.000161	0.000686	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—systemic scleroderma	0.00016	0.000683	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—systemic scleroderma	0.00016	0.000681	CcSEcCtD
Haloperidol—Anorexia—Prednisone—systemic scleroderma	0.000158	0.000673	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—systemic scleroderma	0.000157	0.000668	CcSEcCtD
Haloperidol—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000156	0.000662	CcSEcCtD
Haloperidol—Rash—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000657	CcSEcCtD
Haloperidol—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000656	CcSEcCtD
Haloperidol—Headache—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000653	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—systemic scleroderma	0.000153	0.00065	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—systemic scleroderma	0.000152	0.000647	CcSEcCtD
Haloperidol—Insomnia—Prednisone—systemic scleroderma	0.00015	0.000639	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—systemic scleroderma	0.000147	0.000626	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—systemic scleroderma	0.000146	0.000622	CcSEcCtD
Haloperidol—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000619	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—systemic scleroderma	0.000144	0.000614	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000144	0.000611	CcSEcCtD
Haloperidol—Constipation—Prednisone—systemic scleroderma	0.000142	0.000604	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—systemic scleroderma	0.00014	0.000595	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000139	0.00059	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—systemic scleroderma	0.000137	0.000582	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—systemic scleroderma	0.000136	0.000579	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000136	0.000578	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—systemic scleroderma	0.000135	0.000573	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000134	0.00057	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—systemic scleroderma	0.000132	0.000562	CcSEcCtD
Haloperidol—Urticaria—Prednisone—systemic scleroderma	0.000132	0.000561	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—systemic scleroderma	0.000131	0.000558	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—systemic scleroderma	0.000129	0.000551	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—systemic scleroderma	0.000125	0.000534	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—systemic scleroderma	0.000124	0.000526	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—systemic scleroderma	0.000123	0.000525	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—systemic scleroderma	0.000122	0.00052	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—systemic scleroderma	0.000122	0.000519	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—systemic scleroderma	0.00012	0.000513	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.00012	0.000509	CcSEcCtD
Haloperidol—Pruritus—Prednisone—systemic scleroderma	0.000117	0.0005	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—systemic scleroderma	0.000114	0.000486	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—systemic scleroderma	0.000113	0.000483	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—systemic scleroderma	0.00011	0.000469	CcSEcCtD
Haloperidol—Dizziness—Prednisone—systemic scleroderma	0.00011	0.000467	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—systemic scleroderma	0.00011	0.000466	CcSEcCtD
Haloperidol—Vomiting—Prednisone—systemic scleroderma	0.000105	0.000449	CcSEcCtD
Haloperidol—Rash—Prednisone—systemic scleroderma	0.000105	0.000445	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—systemic scleroderma	0.000104	0.000445	CcSEcCtD
Haloperidol—Headache—Prednisone—systemic scleroderma	0.000104	0.000442	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—systemic scleroderma	0.000102	0.000435	CcSEcCtD
Haloperidol—Nausea—Prednisone—systemic scleroderma	9.85e-05	0.000419	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—systemic scleroderma	9.8e-05	0.000417	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—systemic scleroderma	9.48e-05	0.000404	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—systemic scleroderma	9.16e-05	0.00039	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—systemic scleroderma	8.81e-05	0.000375	CcSEcCtD
Haloperidol—Rash—Methotrexate—systemic scleroderma	8.74e-05	0.000372	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—systemic scleroderma	8.73e-05	0.000372	CcSEcCtD
Haloperidol—Headache—Methotrexate—systemic scleroderma	8.68e-05	0.00037	CcSEcCtD
Haloperidol—Nausea—Methotrexate—systemic scleroderma	8.23e-05	0.000351	CcSEcCtD
